Early stage Hodgkin s lymphoma -Can we avoid Radiotherapy ?

  • 343 views
Uploaded on

This presentation is based on an article published in BLOOD. …

This presentation is based on an article published in BLOOD.
Can we avoid Radiotherapy in early stage Hodgkin lymphoma????

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
343
On Slideshare
0
From Embeds
0
Number of Embeds
2

Actions

Shares
Downloads
23
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Dr Sanudev Sadanandan V P
  • 2. INTRODUCTION
  • 3. WHO classification (2008) 3
  • 4. Staging 4
  • 5. Treatment Groups in Early Stage 5
  • 6. General guidelines for Hodgkin’s Lymphoma treatment 6
  • 7. The current standard is the result of careful clinical trials that demonstrated three principles: i) ABVD is the preferred chemotherapy based on both efficacy and safety, ii) combined-modality therapy (chemotherapy + radiation therapy) is superior to wide-field radiation therapy alone iii) there is no advantage of wide-field radiation therapy over involved-field radiation therapy when given in combination with chemotherapy. 11
  • 8. Combination Chemotherapy Regimens 12
  • 9. 13
  • 10. 14
  • 11.  goal to review this topic and provide context to assist practitioners and patients in their decision-making processes
  • 12. Background  At the beginning of the 20th Century, it was one of the first cancers to demonstrate impressive responses to the “Roentgen Rays  Rene Gilbert,Vera Peters and Henry Kaplan-Hodgkin disease was curable with radiation especially limited stage  development of nitrogen mustard in the 1940s- chemosensitive cancer
  • 13. LYMPH NODAL REGIONS Lymph Nodal Groups 17
  • 14.  Advanced Hodgkin disease is curable -combination chemotherapy (MOPP, ABVD)  potential late complications--secondary leukemia and solid tumors, infertility, cardiovascular and pulmonary disease, but also hypothyroidism, soft tissue effects, and psychosocial effects.
  • 15.  mid-1990 stage I/II ,Favorable --subtotal nodal irradiation (STNI) alone  10-year relapse-free survival-80%  Combining STNI with chemotherapy provided even better outcomes
  • 16. CHEMO ALONE  First reported - early 1970s with MOPP alone-results inconsistent  A Cochrane analysis of clinical trials comparing predominantly alkylator-based chemotherapy alone with CMT, in which the RT component was generally involvedfield treatment, showed superior tumor control and overall survival (OS) in patients treated with CMT.
  • 17.  However, most of the aforementioned trials, including the majority that contributed to the meta-analysis, incorporated chemotherapy regimens now known to be inferior to ABVD and thus do not properly inform current decision-making.
  • 18. Trials evaluating combined modality therapy
  • 19.  Six trials inform decisions to use chemotherapy plus IFRT
  • 20. EORTC H8 Trial  Favorable  age, sex, stage, mediastinal disease, B-symptoms, erythrocyte sedimentation rate [ESR], and histologic subtype).  STNI VS MOPP-ABV X 3cycles + IFRT  RESULT -5-year event-free survival (EFS; 74% vs 98%) - 10-year OS (92% vs 97%) - superior in the CMT arm. Ferme C, Eghbali H et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med. 2007;357(19):1916-1927
  • 21.  Unfavorable patients  MOPP-ABV x 6 cycles + IFRT  MOPP-ABV x4 cycles+ IFRT  MOPP-ABV x 4 cycles +STNI.  RESULTS- No significant differences among the treatment arms were detected for either EFS or OS  Conclusion- STNI alone could no longer be recommended in stage I or II disease and that a reduced volume of radiation fields, from STNI to IFRT, did not compromise outcome.
  • 22.  remaining 4 trials incorporated CMT in all treatment arms and tested radiation field size and/or dose, and types and duration of chemotherapy
  • 23. MILAN TRIAL  ABVDX 4 cycles +STNI  ABVDX 4 cycles + IFRT  29% of patients had unfavorable characteristics (bulky disease, pulmonary hilar disease, E-lesions, or B-symptoms).  RESULT:median follow-up -116 months  Conclusion:no differences were detected in 12-year freedom from progression (93% vs 94%) EFS (87% vs 91%) and OS (96% vs 94%) between the STNI and IFRT arms Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involvedfield radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol. 2004;22(14):2835-2841.
  • 24.  Death-6 deaths/136 patients in this trial 3 from Hodgkin lymphoma 1 cardiovascular event (during ABVD treatment), 1 hepatitis, and 1 acute leukemia.  secondary cancers in the STNI arm-3 , IFRT arm-none  Conclusion: ABVD followed by IFRT could be considered an effective and safe modality in early Hodgkin disease with either favorable or unfavorable presentation.
  • 25. HD10 trial design CS IA, IB, IIA, IIB without RF, N=1190 Randomization Arm A 4 x ABVD Arm B 4 x ABVD Arm C 2 x ABVD Arm D 2 x ABVD 30 Gy 20 Gy 30 Gy 20 Gy (IFRT) (IFRT) (IFRT) (IFRT) Design- non inferiority Trial primary endpoint -freedom from treatment failure (FFTF) median follow-up of 79 months Engert et al. ASH 2009; Abstract 716
  • 26. HD10 trial  Arm D-The 8-year FFTF on this arm(D) of the trial was 86% -8-year survival was 95%.  10 deaths resulting from Hodgkin lymphoma, 12 from toxicity of treatment, 11 from secondary cancer, and 9 from cardiovascular causes.  CONCLUSION- the arm that included 2 cycles of ABVD and 20 Gy IFRT was considered to be noninferior with respect to FFTF and was associated with less severe toxicity and was thus concluded by the authors to be optimum therapy.
  • 27. HD11 trial design CS I, IIA with risk factors a-d, CS IIB with risk factors c, d (a: large mediastinal mass, b: extranodal involvement, c: elevated ESR, d: ≥3 nodal areas) Randomization 4xABVD 4xABVD 4xBEACOPP 4xBEACOPP 30 Gy 20 Gy 30 Gy 20 Gy (IFRT) (IFRT) (IFRT) (IFRT) Arm A Arm B Arm C Arm D Borchmann et al. ASH 2009; Abstract 717 GHSG 2009 – HD11
  • 28. HD11 trial  primary endpoint – FFTF  median follow-up of 82 months  Results:  5-year FFTF was inferior in the 4 ABVD 20 Gy arm (81% vs 85%-87%), although no difference in 5-year survival (94%-95%) was observed
  • 29.  4 ABVD+30 Gy arm was concluded to be noninferior to the BEACOPP regimens and was recommended as the treatment of choice because of the greater toxicity of BEACOPP  among these 356 patients, the 5-year FFTF was 85% and survival was 94%  7 deaths from Hodgkin lymphoma, 5 from treatment toxicity, 3 from secondary cancers, and 5 from cardiovascular causes.
  • 30. Stanford G4 study.  single arm trial of Stanford V chemotherapy plus 30 Gy IFRT.  Stanford and the Northern California Kaiser Hospitals.  stage I or II disease  Exclusion-B-symptoms or large mediastinal adenopathy  Stanford V chemotherapy x8weeks +30 Gy “modified” IFRT  N= 87 ,median follow up was 10.6 years.  The 10-year freedom from disease progression and OS are both 94%.
  • 31.  There were 4 deaths: 2 from transplantationrelated complications, one from metastatic colon cancer, and one from swine flu.  The authors concluded that this regimen was safe and highly effective.
  • 32. TRIALS EVALUATING CHEMOTHERAPY ALONE
  • 33. National Cancer Institute of Canada (NCIC) Clinical Trials Group (NCIC CTG) Eastern Cooperative Oncology Group (ECOG) HD.6 trial  patients with nonbulky stage I or IIA disease were randomized to receive ABVD alone or radiation-based treatment.  unfavorable cohorts: those with any one of age 40 years, ESR 50, mixed cellularity or lymphocyte depleted histology, and/or 3 or more disease sites  control arm, those in the favorable-risk cohort received STNI alone, unfavorable risk cohort patients received 2 cycles of ABVD followed by STNI.  Experimental arm: therapy was the same for both risk groups: 4-6 cycles of ABVD, with the number of cycles dependent on rapidity of response documented by computed tomographic imaging
  • 34.  N=405 patients, eligible- 399  primary outcome was 12-year survival  median follow up of 11.3 years  12-year survival was superior in patients randomized to receive chemotherapy alone (94% vs 87%; hazard ratio [HR] 0.05; P .04)  12-year freedom from progressive disease (FFPD) was inferior (87% vs 92%; HR 1.91; P .05)
  • 35.  The difference in OS was attributed to fewer deaths from causes other than progressive Hodgkin lymphoma in those allocated to ABVD alone (6 vs 20)  deaths from progressive Hodgkin lymphoma were similar (6 vs 4).  There were 10 deaths from second cancers among those assigned to radiation and 4 in those randomized to ABVD alone
  • 36.  In subset analyses  no differences in either 12-year FFPD (89% vs 87%; HR 0.88; P .82) or 12-year survival (98% vs 98%; HR 1.09; P .95) were detected between the ABVD alone and radiation therapy groups among the favorable cohorts.  In the unfavorable cohorts, 12-year FFPD was inferior in those allocated to ABVD (86% vs 94%; HR 3.23; P .006), whereas 12-year survival was superior (92% vs 81%; HR 0.47; P .04).
  • 37.  CONCLUSION:  Treatment with ABVD alone is associated with superior long-term OS because it is associated with fewer deaths from other causes
  • 38. THE TREATMENT OF LIMITED-STAGE HODGKIN LYMPHOMA: A RADIATION ONCOLOGIST’S PERSPECTIVE
  • 39. Is radiation therapy alone ever an option for the treatment of early-stage Hodgkin lymphoma?  The use of radiation therapy alone for the treatment of classic Hodgkin lymphoma was abandoned more than a decade ago.  Clinical trials comparing STNI and CMT demonstrated an improved EFS,low toxicity for CMT  Hence in classical Hodgkin lymphoma CMT is the standard treatment EORTC,MILAN,HD10,HD11
  • 40. Nodular lymphocyte predominant Hodgkin lymphoma The GHSG evaluated retrospectively patients treated on their sequential trials with extended-field RT (EFRT), CMT, or IFRT and found no differences in outcome related to the intensity of therapy.  ESMO&NCCN guidelines recommend IFRT alone -stage I disease stage II disease-OPTION
  • 41. What extent of irradiation is indicated in the setting of combined modality therapy?  IFRT is accepted as the standard in combined modality therapy programs for stage 1A,IIA MILAN TRIAL HD10 HD11
  • 42. What about chemotherapy alone for nonbulky stage I or II Hodgkin lymphoma?  NCIC CTG HD6  favorable cohort--no significant difference in outcome between treatment with ABVD or STNI  unfavorable cohort--12-year OS after ABVD treatment was 92% and the freedom from disease progression was 86%. The OS in the radiation-containing regimen (ABVDx2 plus STNI) was only 81%, despite the superior freedom from disease progression (94%).
  • 43.  extent of radiation used was outdated and that this was likely to have contributed to the excess deaths  NCIC CTG trial used RT that violates current standards with respect to both volume and dose of irradiation in the CMT setting.
  • 44. What criticisms or concerns does the NCIC CTG trial raise for radiation oncologists?  current standard for radiation volume in combined modality therapy programs is IFRT. STNI exceeds the volume of IFRT by 3to 5-fold  IFRT -lower doses to the breasts, lungs, and heart in nearly all cases  All irradiated patients treated to their clinically uninvolved spleens and para-aortic nodes, exposing them to risks of infection, cardiac disease, and secondary malignancy.  Involved field irradiation for these patients would never have included those volumes
  • 45.  All women ,who were irradiated received irradiation to bilateral axillary nodes, exposing them to a risk of breast cancer, although it is probable that no more than 25% of women would have had either axilla irradiated with IFRT and the reduction in mean breast tissue dose would be 65%.  All irradiated patients in this trial had treatment to the entire mediastinum, exposing them to cardiac risks, whereas this would not have been the case for patients treated with IFRT who had an uninvolved mediastinum
  • 46.  The risk for radiation-related cancer is proportional to the volume irradiated  irradiation of smaller volumes is associated with a lower risk for breast cancer in women and so patients irradiated in this trial were at greater risk for radiation-related complications than if they had been treated with IFRT.  risk for cardiac complications increases as the volume of heart irradiated increases
  • 47. Dose  radiation dose -35 Gy  current recommendation(I,II)-20-30Gy  Increased risk-2nd malignancy,cardiaac risk
  • 48. Deaths  23 deaths among the 139 patients in the ABVD plus STNI group. This included 9 deaths from secondary cancer.  There were 2 deaths from cardiac events (identical to the ABVD arm), 3 from infection, and one each from Alzheimer disease, drowning, suicide, respiratory failure, and unknown.
  • 49.  The impact of these deaths resulted in a 12-year OS for ABVD plus STNI of only 81%.  The number of patients who developed any second cancer was 23 in the radiation therapy groups and 10 in the ABVD group.  Among the 23 cancers in the radiation therapy group, location relative to the radiation fields is not noted; however, 6 were in the pelvis and unlikely to have been irradiated
  • 50.  The risk that radiation oncologists perceive is that these results will be interpreted incorrectly to imply a negative impact for radiation Therapy  Many of the risks associated with radiation therapy in this trial would not be risks with contemporary radiation therapy
  • 51.  Another risk that radiation oncologists perceive is that these results will be translated into clinical practice for patients with bulky stage Ior II Hodgkin lymphoma.  This trial only addressed patients with nonbulky disease.  Patients with bulky disease are at greater risk for relapse, and clinical trials of the EORTC and GHSG, which incorporate radiation therapy, should be used to inform treatment practice for these patients
  • 52. What is the current standard for radiation therapy in combined modality therapy?  Standard-IFRT--treatment to the entirety of a lymphoid region  involved node radiotherapy (INRT) -Developed by EORTC/GELA  - irradiated volume is less and a smaller volume of radiation treatment must be associated with less risk for late effects
  • 53. What does the future hold for the management of patients with early-stage Hodgkin lymphoma?  We need Adaptive treatment.  NCCN already recommends chemotherapy alone or combined modality therapy.  The NCIC CTG trial incorporated adaptive therapy in defining the number of cycles of chemotherapy to be used (4-6) based on the rapidity of a complete response. However, more than 60% of patients were treated with 6 cycles of ABVD according to this trial design.
  • 54.  Ideally, if IFRT can be effective in preventing relapse, it could be refined even further (eg, INRT)  reducing the number of cycles of chemotherapy from 4-6 to as few as 2, and thereby reducing the potential late risks of chemotherapy
  • 55.  Identification of those patients most likely to benefit from the addition of radiation therapy remains a challenge.  A promising technique is interim positron emission tomography (PET) imaging, following 2 or 3 cycles of chemotherapy, to identify patients with a slow or inadequate response to chemotherapy.  Currently, clinical trials in the GHSG (HD16), EORTC-GELA (H10), and in the United Kingdom (RAPID Trial) are testing this concept
  • 56. THE TREATMENT OF LIMITEDSTAGE HODGKIN LYMPHOMA: A HEMATOLOGIST’S PERSPECTIVE
  • 57.  Treatment options -nonbulky stage I or IIA  1.CMT 2-4 cycles of ABVD + IFRT (GHSG HD10, HD11 trials)  2.chemotherapy alone with ABVD(NCIC CTG/ECOG HD6 trial)  There is no RCT comparing these 2 options
  • 58.  In this section, a synthesis will be provided to argue that treatment with ABVD alone is reasonable, appropriate and, for many patients, may be preferred.  This information will be presented in 4 tiers: 1.reports of primary results 2. interpretation of other trial-specific conclusions 3. integration of hypothesis-generating data 4.additional context and supposition.
  • 59. first tier  objective -compare the 12-year survivals of patients with nonbulky stage I or IIA Hodgkin lymphoma treated with ABVD alone with patients given treatment that included STNI  At 12 years, OS  94% -assigned to ABVD alone ,87% -STNI  with differences because of more deaths in the STNI arm from causes other than progressive Hodgkin lymphoma or early treatment complication (20 vs 6)
  • 60.  HD.6 trial illustrates the dilemma of evaluating long- term OS as the primary endpoint in a limited-stage Hodgkin lymphoma trial  therapeutic advances will undoubtedly occur in the interim  In this case, advances include recognition that STNI is excessive, outdated, and probably contributed to the results and conclusions.
  • 61. second tier  3 results from HD.6 and associated conclusions form a second tier of evidence and best inform today’s decisionmaking.  These findings relate to disease control and survival outcomes of patients assigned to ABVD alone and to the topic of surrogate outcomes.  The observed 12-year FFPD associated with ABVD was 87%. These results were inferior to those observed in the HD.6 control arm (92%) and might be assumed to be inferior to those associated with modern CMT.
  • 62.  Logical extensions might then suggest that treatment that includes IFRT will have fewer late effects than observed with HD.6 control arm therapy, meaning that modern CMT may be associated with superior disease control, a reduced need for subsequent therapy, fewer late effects, and OS that is as good or better than observed with ABVD alone. However, important existing data do not support these assumptions
  • 63. CONCLUSION  we have witnessed in our lifetimes dramatic improvements in the treatment of Hodgkin lymphoma, a disease that previously had been considered to be fatal.  This progress has been the result of detailed clinical observations, carefully conducted clinical trials, the refinement of existing treatments, the development of novel therapies, and the collaboration of specialists across the breadth of medicine.  Functional assays, genetic profiling, and the introduction of biologic therapies all hold promise for the future and may enable us to be more selective in defining treatment for individual patients.   The existing debate will become moot when these advances are realized.
  • 64.  THANK YOU
  • 65. Adverse Prognostic Factors The International Prognostic Score (IPS) is based on seven factors: three clinical and four laboratory values . Patients are given a score of from 0 to 7, and disease can be categorized as low (0–1), intermediate (2–3), or high (4–7) risk. 82